The American Journal of Managed Care® presents its annual special issue of Evidence-Based Oncologyâ„¢ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.
FOR IMMEDIATE RELEASEJanuary 27, 2017
CRANBURY, N.J.—Finding the balance between excitement over new ways to treat blood cancers and how to pay for them has been a recurrent theme at recent meetings of the American Society of Hematology, and the gathering December 3-6, 2016, in San Diego, Calif., was no exception. For an overview of the 58th annual meeting, The American Journal of Managed Care® has published its special issue of Evidence-Based Oncology™ (EBO™), featuring scientific updates and session coverage.
Despite a few deaths in clinical trials, treatments featuring chimeric antigen receptor (CAR) T cells, either alone or in combination with other therapies, gained plenty of notice. The new issue reports on successes in patients with chronic lymphocytic leukemia (CLL) who have already received Imbruvia (ibrutinib), as well as biomarkers that can determine which patients will fare best.
The issue includes coverage of the Choosing Wisely® Task Force and Champions, who shared how they strive to deliver the right amount of care—and avoid unnecessary costs and burdens on patients. As always, EBO™ coverage includes both clinical updates and coverage from sessions that address the cost of new treatments, management of side effects, and the promise and challenges of Health IT.
Surabhi Dangi-Garimella, PhD, managing editor of EBO™, produced the special issue.
About the Journals and AJMC.com
The American Journal of Managed Care® is the leading peer-reviewed journal dedicated to issues in managed care. AJMC.com distributes healthcare news to leading stakeholders across a variety of platforms. Other titles in the franchise include The American Journal of Accountable Care®, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act, and The American Journal of Pharmacy Benefits.® AJMC®’s Evidence-Based series brings together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC® publications, please call (609) 716-7777, x 224.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More